The HIV-1 Entry Process: A Stoichiometric View

Trends in Microbiology

Volumn 23, Issue 12, 2015, Pages 763-774

  Brandenberg, Oliver F ^a,c   Magnus, Carsten ^a   Regoes, Roland R ^b   Trkola, Alexandra ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c California Institute of Technology   (United States)

Author keywords

Antibody neutralization; Envelope trimer; HIV 1 entry; HIV 1 transmission; Membrane fusion; Stoichiometry

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ASSAY; DISEASE COURSE; ELECTRON MICROSCOPY; FLUORESCENCE MICROSCOPY; HOST CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STOICHIOMETRY; VIRION; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS STRAIN; VIRUS TRANSMISSION; ANTIBODY AFFINITY; BIOLOGICAL MODEL; CELL MEMBRANE; CHEMISTRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MEMBRANE FUSION; PHYSIOLOGY; VIROLOGY; VIRUS ACTIVATION;

ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; CELL MEMBRANE; HIV INFECTIONS; HIV-1; HUMANS; MEMBRANE FUSION; MODELS, IMMUNOLOGICAL; VIRAL ENVELOPE PROTEINS; VIRION; VIRUS ACTIVATION; VIRUS INTERNALIZATION;

EID: 84960843250     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2015.09.003     Document Type: Review

References (97)

1. Layne S.P., et al. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology 1992, 189:695-714.
2. Chertova E., et al. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 2002, 76:5315-5325.
3. Zhu P., et al. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:15812-15817.
4. Zhu P., et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006, 441:847-852.
5. Chojnacki J., et al. Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy. Science 2012, 338:524-528.
6. Brandenberg O.F., et al. Different infectivity of HIV-1 strains is linked to number of envelope trimers required for entry. PLoS Pathog. 2015, 11:e1004595.
7. Pang Y., et al. Optical trapping of individual human immunodeficiency viruses in culture fluid reveals heterogeneity with single-molecule resolution. Nat. Nanotechnol. 2014, 9:624-630.
8. Checkley M.A., et al. HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J. Mol. Biol. 2011, 410:582-608.
9. Weissenhorn W., et al. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997, 387:426-430.
10. Klasse P.J. The molecular basis of HIV entry. Cell. Microbiol. 2012, 14:1183-1192.
11. Wilen C.B., et al. Molecular mechanisms of HIV entry. Adv. Exp. Med. Biol. 2012, 726:223-242.
12. Yang X., et al. Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J. Virol. 2005, 79:12132-12147.
13. Klasse P.J. Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody. Virology 2007, 369:245-262.
14. Herrera C., et al. Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex. Virology 2006, 351:121-132.
15. Magnus C., et al. Estimating the stoichiometry of human immunodeficiency virus entry. J. Virol. 2009, 83:1523-1531.
16. Kuhmann S.E., et al. Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J. Virol. 2000, 74:7005-7015.
17. Zarr M., Siliciano R. Stoichiometric parameters of HIV-1 entry. Virology 2015, 474:1-9.
18. Sougrat R., et al. Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. PLoS Pathog. 2007, 3:e63.
19. Yang X., et al. Subunit stoichiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into host cells. J. Virol. 2006, 80:4388-4395.
20. Magnus C., Regoes R.R. Analysis of the subunit stoichiometries in viral entry. PLoS ONE 2012, 7:e33441.
21. Brandenberg O.F., et al. Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation. Retrovirology 2014, 11:75.
22. Moore P.L., et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J. Virol. 2006, 80:2515-2528.
23. Poignard P., et al. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J. Virol. 2003, 77:353-365.
24. Crooks E.T., et al. Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected. J. Virol. 2011, 85:5825-5839.
25. Earl L.A., et al. Catching HIV 'in the act' with 3D electron microscopy. Trends Microbiol. 2013, 21:397-404.
26. Muller B., Heilemann M. Shedding new light on viruses: super-resolution microscopy for studying human immunodeficiency virus. Trends Microbiol. 2013, 21:522-533.
27. Liu J., et al. 3D visualization of HIV virions by cryoelectron tomography. Meth. Enzymol. 2010, 483:267-290.
28. Liu J., et al. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008, 455:109-113.
29. Lyumkis D., et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1484-1490.
30. Grove J. Super-resolution microscopy: a virus' eye view of the cell. Viruses 2014, 6:1365-1378.
31. Harrison S.C. Viral membrane fusion. Virology 2015, 479-480C:498-507.
32. Myszka D.G., et al. Energetics of the HIV gp120-CD4 binding reaction. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:9026-9031.
33. Blumenthal R., et al. HIV entry and envelope glycoprotein-mediated fusion. J. Biol. Chem. 2012, 287:40841-40849.
34. Chernomordik L.V., Kozlov M.M. Protein-lipid interplay in fusion and fission of biological membranes. Annu. Rev. Biochem. 2003, 72:175-207.
35. Kwong P.D., et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002, 420:678-682.
36. Guttman M., et al. CD4-induced activation in a soluble HIV-1 Env trimer. Structure 2014, 22:974-984.
37. Haim H., et al. Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-Independent infection and global inhibitor sensitivity. PLoS Pathog. 2011, 7:e1002101.
38. White T.A., et al. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog. 2010, 6:e1001249.
39. Finzi A., et al. Lineage-specific differences between human and simian immunodeficiency virus regulation of gp120 trimer association and CD4 binding. J. Virol. 2012, 86:8974-8986.
40. Gallo S.A., et al. The HIV Env-mediated fusion reaction. Biochim. Biophys. Acta 2003, 1614:36-50.
41. Melikyan G.B. Membrane fusion mediated by human immunodeficiency virus envelope glycoprotein. Curr. Top. Membr. 2011, 68:81-106.
42. Mkrtchyan S.R., et al. Ternary complex formation of human immunodeficiency virus type 1 Env CD4, and chemokine receptor captured as an intermediate of membrane fusion. J. Virol. 2005, 79:11161-11169.
43. Jolly C., et al. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J. Exp. Med. 2004, 199:283-293.
44. Sattentau Q. Avoiding the void: cell-to-cell spread of human viruses. Nat. Rev. Microbiol. 2008, 6:815-826.
45. Murooka T.T., et al. HIV-infected T cells are migratory vehicles for viral dissemination. Nature 2012, 490:283-287.
46. Agosto L.M., et al. HIV cell-to-cell transmission: effects on pathogenesis and antiretroviral therapy. Trends Microbiol. 2015, 23:289-295.
47. Dale B.M., et al. Mechanisms of enhanced HIV spread through T-cell virological synapses. Immunol. Rev. 2013, 251:113-124.
48. Zhong P., et al. Cell-to-cell transmission can overcome multiple donor and target cell barriers imposed on cell-free HIV. PLoS ONE 2013, 8:e53138.
49. Russell R.A., et al. Multiple proviral integration events after virological synapse-mediated HIV-1 spread. Virology 2013, 443:143-149.
50. Chen P., et al. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J. Virol. 2007, 81:12582-12595.
51. Del Portillo A., et al. Multiploid inheritance of HIV-1 during cell-to-cell infection. J. Virol. 2011, 85:7169-7176.
52. Yen P.J., et al. Loss of a conserved N-linked glycosylation site in the simian immunodeficiency virus envelope glycoprotein V2 region enhances macrophage tropism by increasing CD4-independent cell-to-cell transmission. J. Virol. 2014, 88:5014-5028.
53. Platt E.J., et al. Rapid dissociation of HIV-1 from cultured cells severely limits infectivity assays, causes the inactivation ascribed to entry inhibitors, and masks the inherently high level of infectivity of virions. J. Virol. 2010, 84:3106-3110.
54. Platt E.J., et al. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J. Virol. 2005, 79:4347-4356.
55. Leaman D.P., Zwick M.B. Increased functional stability and homogeneity of viral envelope spikes through directed evolution. PLoS Pathog. 2013, 9:e1003184.
56. Ruprecht C.R., et al. MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. J. Exp. Med. 2011, 208:439-454.
57. Schiffner T., et al. Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies. Vaccine 2013, 31:5789-5797.
58. Kozlov M.M., Chernomordik L.V. A mechanism of protein-mediated fusion: coupling between refolding of the influenza hemagglutinin and lipid rearrangements. Biophys. J. 1998, 75:1384-1396.
59. Kuzmin P.I., et al. A quantitative model for membrane fusion based on low-energy intermediates. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:7235-7240.
60. Yang S.T., et al. HIV gp41-mediated membrane fusion occurs at edges of cholesterol-rich lipid domains. Nat. Chem. Biol. 2015, 11:424-431.
61. Prasad V.R., Bukrinsky M.I. New clues to understanding HIV nonprogressors: low cholesterol blocks HIV trans infection. MBio 2014, 5:e01396-e1414.
62. Melikyan G.B. HIV entry: a game of hide-and-fuse?. Curr. Opin. Virol. 2014, 4:1-7.
63. Joseph S.B., et al. Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities. J. Virol. 2014, 88:1858-1869.
64. + T-cells than envelopes highly adapted for macrophages. Retrovirology 2015, 12:25.
65. Platt E.J., et al. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 1998, 72:2855-2864.
66. Pluckthun A. HIV: Antibodies with a split personality. Nature 2010, 467:537-538.
67. Klein J.S., Bjorkman P.J. Few and far between: how HIV may be evading antibody avidity. PLoS Pathog. 2010, 6:e1000908.
68. Galimidi R.P., et al. Intra-spike crosslinking overcomes antibody evasion by HIV-1. Cell 2015, 160:433-446.
69. Klein J.S., et al. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:7385-7390.
70. Crooks E.T., et al. Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization. Virology 2008, 377:364-378.
71. Yasmeen A., et al. Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology 2014, 11:41.
72. Platt E.J., et al. Kinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:7829-7834.
73. Parrish N.F., et al. Phenotypic properties of transmitted founder HIV-1. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:6626-6633.
74. Parrish N.F., et al. Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin alpha4beta7. PLoS Pathog. 2012, 8:e1002686.
75. Lynch R.M., et al. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. J. Virol. 2015, 89:4201-4213.
76. Sather D.N., et al. Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virus. J. Virol. 2012, 86:12676-12685.
77. Walker L.M., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
78. Wu X., et al. Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies. J. Virol. 2011, 85:4578-4585.
79. Wild C., et al. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses 1993, 9:1051-1053.
80. West A.P., et al. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 2014, 156:633-648.
81. Burton D.R., Mascola J.R. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 2015, 16:571-576.
82. Bentz J. Membrane fusion mediated by coiled coils: a hypothesis. Biophys. J. 2000, 78:886-900.
83. Ivanovic T., et al. Influenza-virus membrane fusion by cooperative fold-back of stochastically induced hemagglutinin intermediates. Elife 2013, 2:e00333.
84. Floyd D.L., et al. Single-particle kinetics of influenza virus membrane fusion. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:15382-15387.
85. Danieli T., et al. Membrane fusion mediated by the influenza virus hemagglutinin requires the concerted action of at least three hemagglutinin trimers. J. Cell Biol. 1996, 133:559-569.
86. Blumenthal R., et al. Dilation of the influenza hemagglutinin fusion pore revealed by the kinetics of individual cell-cell fusion events. J. Cell Biol. 1996, 135:63-71.
87. Padmanabhan P., Dixit N.M. Mathematical model of viral kinetics in vitro estimates the number of E2-CD81 complexes necessary for hepatitis C virus entry. PLoS Comput. Biol. 2011, 7:e1002307.
88. Mohrmann R., et al. Fast vesicle fusion in living cells requires at least three SNARE complexes. Science 2010, 330:502-505.
89. Shi L., et al. SNARE proteins: one to fuse and three to keep the nascent fusion pore open. Science 2012, 335:1355-1359.
90. Sinha R., et al. Two synaptobrevin molecules are sufficient for vesicle fusion in central nervous system synapses. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:14318-14323.
91. Chernomordik L.V., Kozlov M.M. Mechanics of membrane fusion. Nat. Struct. Mol. Biol. 2008, 15:675-683.
92. Pang H.B., et al. Virion stiffness regulates immature HIV-1 entry. Retrovirology 2013, 10:4.
93. Kwong P.D., Mascola J.R. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012, 37:412-425.
94. Magnus C., Regoes R.R. Estimating the Stoichiometry of HIV Neutralization. PLoS Comput. Biol. 2010, 6:e1000713.
95. Yang X., et al. Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. J. Virol. 2005, 79:3500-3508.
96. Magnus C., Regoes R.R. Restricted occupancy models for neutralization of HIV virions and populations. J. Theor. Biol. 2011, 283:192-202.
97. Burton D.R., et al. A model for neutralization of viruses based on antibody coating of the virion surface. Curr. Top. Microbiol. Immunol. 2001, 260:109-143.